

**Lisa Salberg**  
CEO and Founder  
Hypertrophic Cardiomyopathy Association  
66 Ford Road, Suite 213 B  
Denville, NJ 07834  
973-727-2450  
Lisa@4hcm.org

---

**Work Experience:**

Hypertrophic Cardiomyopathy Association, Founder and CEO  
1996-present

Packard Industries, Human Resource Manager and Health Plan Administrator  
1988-2005

**Federal Grants:**

Subcontractor LIVE-HCM NIH Trial, NCT02549664

**Faculty/Invited Speaker:**

HCM International Summit 1997, 2002, 2006, 2009, 2013, 2017, 2021, 2024  
NYU Langone Health's Management Decisions in Hypertrophic Cardiomyopathy, 2012, 2014, 2016, 2020, 2023  
Florence International Symposium on Advances in CARDIOMyopathies, 2013, 2015  
San Diego Heart Failure Symposium, 2019, 2021, 2024  
First Latin American Hypertrophic Cardiomyopathy Summit: 2025

**Conference Attendee:**

HFSA Annual Scientific Meeting, 2019, 2020, 2021, 2022, 2023  
American Heart Association, 2009, 2011, 2014, 2018, 2020 ( virtual), 2022, 2023, 2024, 2025  
American College Cardiology, 2012, 2013, 2014, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026  
European Society of Cardiology, 2012, 2023, 2024, 2025  
American Society of Echocardiography, 2023, 2024, 2025

**Externally Led-Patient Focused Drug Development Meetings:**

2020 - HCM what the FDA needs to know about the HCM community, June 26, 2020  
2026 - Genetic Cardiomyopathies - educating the FDA on the need for gene-based approaches to care April 23, 2026

**Partners:**

**Industry**

Bayer, BioMarin, Bristol Myers Squibb, Cardio Genomics, Cytokinetics, Edgewise Therapeutics, Imbria Pharmaceuticals, Pfizer, Tenaya Therapeutics, Nest Genomics, Melinta Therapeutics, Alnyln, BridgeBio and more...

## Non Profit

National Health Council, American College of Cardiology, American Heart Association, American Society of Echocardiography, Angel Flight East, Arrhythmia Alliance, Genetics Cardiomyopathy Awareness Consortium, Global Heart Hub, HCM Society, HeartBrothers House, Heart Failure Society of America, Heart Valve Voice, In A Heartbeat, National Forum, StopAfib.org, Preventive Cardiovascular Nurses Association, WomenHeart, Partnership to Advance Cardiovascular Health, Reasonable Accommodations

## Books, Peer Reviewed Publications, and Writing Committees:

1. Lampert R, Day S, Ainsworth B, Burg M, Marino BS, **Salberg, L.**, Tome Esteban MT, Abrams DJ, Aziz PF, Barth C, Behr ER, Bell C, Berul CI, Bos JM, Bradley D, Cannom DS, Cannon BC, Concannon MA, Cerrone M, Czosek RJ, Dubin AM, Dziura J, Erickson CC, Estes NAM 3rd, Etheridge SP, Goldenberg I, Gray B, Haglund-Turnquist C, Harmon K, James CA, Johnsrude C, Kannankeril P, Lara A, Law IH, Li F, Link MS, Molossi SM, Olshansky B, Noseworthy PA, Saarel EV, Sanatani S, Shah M, Simone L, Skinner J, Tomaselli GF, Ware JS, Webster G, Zareba W, Zipes DP, Ackerman MJ. Vigorous Exercise in Patients With Congenital Long QT Syndrome: Results of the Prospective, Observational, Multinational LIVE-LQTS Study. *Circulation*. 2024 Aug 13;150(7):516-530. Doi: 10.1161/CIRCULATIONAHA.123.067590. Epub 2024 Jul 25. PMID: 39051104.
2. **Salberg, L.** Hypertrophic Cardiomyopathy: The Patient Perspective-Turning Tragedy into Action (2024). *Am J Cardiol*. 2024 Feb 1;212S:S83-S86. doi: 10.1016/j.amjcard.2023.10.063. Epub 2024 Jan 29. PMID: 38368040.
3. Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, **Salberg, L.**, Tome Esteban MT, Ho CY, Abraham R, Balaji S, Barth C, Berul CI, Bos M, Cannom D, Choudhury L, Concannon M, Cooper R, Czosek RJ, Dubin AM, Dziura J, Eidem B, Emery MS, Estes NAM, Etheridge SP, Geske JB, Gray B, Hall K, Harmon KG, James CA, Lal AK, Law IH, Li F, Link MS, McKenna WJ, Molossi S, Olshansky B, Ommen SR, Saarel EV, Saberi S, Simone L, Tomaselli G, Ware JS, Zipes DP, Day SM; LIVE Consortium. Vigorous Exercise in Patients With Hypertrophic Cardiomyopathy. *JAMA Cardiol*. 2023 Jun 1;8(6):595-605. doi: 10.1001/jamacardio.2023.1042. PMID: 37195701; PMCID: PMC10193262.
4. Lampert, R., Ackerman, M., Marino., B., Burg, M., Ainsworth, B., **Salberg, L.**, et al. (2023). Vigorous Exercise in Patients with Hypertrophic Cardiomyopathy. *JAMA Cardiology*, 8(6), 595–605. <https://doi.org/10.1001/jamacardio.2023.1042>
5. Borsari, W., Davis, L., Meiers, E., **Salberg, L.**, & Barbara McDonough (2022). Living with hypertrophic cardiomyopathy: a patient's perspective. *Future cardiology*, 18(1), 43–50. <https://doi.org/10.2217/fca-2021-0091>
6. Asbeutah, A. A. A., Ingram, E., Mouksian, K., Wilbanks, D., Alexander, J., Bath, A., **Salberg, L.**, & Jefferies, J. L. (2022). Psychological Symptoms and Physical Limitations With Hypertrophic Cardiomyopathy. *The American Journal of cardiology*, 174, 179–180. <https://doi.org/10.1016/j.amjcard.2022.03.031>

7. **Salberg, L.** (2022). The role of patient advocacy in hypertrophic cardiomyopathy: The 25-year journey of the HCMA. *Asian Cardiovascular & thoracic annals*, 30(1), 8–10. <https://doi.org/10.1177/02184923211058446>
8. Hudson, J., Sturm, A. C., **Salberg, L.**, Brennan, S., Quinn, G. P., & Vadaparampil, S. T. (2019). Disclosure of diagnosis to at-risk relatives by individuals diagnosed with hypertrophic cardiomyopathy (HCM). *Journal of community genetics*, 10(2), 207–217. <https://doi.org/10.1007/s12687-018-0377-1>
9. Ahmad, F., McNally, E. M., Ackerman, M. J., Baty, L. C., Day, S. M., Kullo, I. J., Madueme, P. C., Maron, M. S., Martinez, M. W., **Salberg, L.**, Taylor, M. R., & Wilcox, J. E. (2019). Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. *Circulation. Genomic and precision medicine*, 12(6), e000054. <https://doi.org/10.1161/HCG.0000000000000054>
10. Papoutsidakis, N., Heitner, S., Ingles, J., Semsarian, C., Mannello, M., **Salberg, L.**, Waldman, C., Vaccaro, B., Maurizi, N., Olivotto, I., & Jacoby, D. (2019). Participation in thrill-seeking activities by patients with hypertrophic cardiomyopathy: Individual preferences, adverse events and physician attitude. *American heart journal*, 214, 28–35. <https://doi.org/10.1016/j.ahj.2019.04.001>
11. Baskar, S., Jefferies, J. L., **Salberg, L.**, Khoury, P. R., Spar, D. S., Knilans, T. K., & Czosek, R. J. (2018). Patient understanding of disease and the use and outcome of implantable cardioverter defibrillators in hypertrophic cardiomyopathy. *Pacing and clinical electrophysiology : PACE*, 41(1), 57–64. <https://doi.org/10.1111/pace.13234>
12. Batte, B., Sheldon, J. P., Arscott, P., Huismann, D. J., **Salberg, L.**, Day, S. M., & Yashar, B. M. (2015). Family communication in a population at risk for hypertrophic cardiomyopathy. *Journal of genetic counseling*, 24(2), 336–348. <https://doi.org/10.1007/s10897-014-9774-8>
13. Lawless, C. E., Asplund, C., Asif, I. M., Courson, R., Emery, M. S., Fuisz, A., Kovacs, R. J., Lawrence, S. M., Levine, B. D., Link, M. S., Martinez, M. W., Matherne, G. P., Olshansky, B., Roberts, W. O., **Salberg, L.**, Vetter, V. L., Vogel, R. A., & Whitehead, J. (2014). Protecting the heart of the American athlete: Proceedings of the American College of Cardiology Sports and Exercise Cardiology Think Tank October 18, 2012, Washington, DC. *Journal of the American College of Cardiology*, 64(20), 2146–2171. <https://doi.org/10.1016/j.jacc.2014.08.027>
14. Maron, B.J. and **Salberg, L.** (2014). *Hypertrophic Cardiomyopathy: For patients, their families and interested physicians* (3rd ed.). Wiley-Blackwell.
15. Maron, B. J., Friedman, R. A., Kligfield, P., Levine, B. D., Viskin, S., Chaitman, B. R., Okin, P. M., Saul, J. P., **Salberg, L.**, Van Hare, G. F., Soliman, E. Z., Chen, J., Matherne, G. P., Bolling, S. F., Mitten, M. J., Caplan, A., Balady, G. J., Thompson, P. D., & American Heart Association Council on Clinical Cardiology, Advocacy Coordinating Committee, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Surgery and Anesthesia, Council on Epidemiology and Prevention, Council on Functional Genomics and

Translational Biology, Council on Quality of Care and Outcomes Research, and American College of Cardiology (2014). Assessment of the 12-lead ECG as a screening test for detection of cardiovascular disease in healthy general populations of young people (12-25 Years of Age): a scientific statement from the American Heart Association and the American College of Cardiology. *Circulation*, 130(15), 1303–1334.  
<https://doi.org/10.1161/CIR.0000000000000025>

16. **Salberg, L.** (2013). Research on children with hypertrophic cardiomyopathy. *Journal of the American College of Cardiology*, 61(2), 211. <https://doi.org/10.1016/j.jacc.2012.07.071>
17. Reineck, E., Rolston, B., Bragg-Gresham, J. L., **Salberg, L.**, Baty, L., Kumar, S., Wheeler, M. T., Ashley, E., Saberi, S., & Day, S. M. (2013). Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. *The American journal of cardiology*, 111(7), 1034–1039. <https://doi.org/10.1016/j.amjcard.2012.12.018>
18. Kramer, D. B., Kesselheim, A. S., **Salberg, L.**, Brock, D. W., & Maisel, W. H. (2011). Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy. *The American journal of cardiology*, 107(7), 1071–1075.e5. <https://doi.org/10.1016/j.amjcard.2010.11.036>
19. Lampert, R., **Salberg, L.**, & Burg, M. (2010). Emotional stress triggers symptoms in hypertrophic cardiomyopathy: a survey of the Hypertrophic Cardiomyopathy Association. *Pacing and clinical electrophysiology : PACE*, 33(9), 1047–1053.  
<https://doi.org/10.1111/j.1540-8159.2010.02770.x>
20. Lara, A. A., & **Salberg, L.** (2009). Patient advocacy: what is its role?. *Pacing and clinical electrophysiology: PACE*, 32 Suppl 2, S83–S85.  
<https://doi.org/10.1111/j.1540-8159.2009.02392.x>
21. **Salberg, L.** (2008). GINA update. *Journal of cardiovascular translational research*, 1(1), 9–10. <https://doi.org/10.1007/s12265-008-9013-5>
22. Maron, B. J., Bonow, R. O., **Salberg, L.**, Roberts, W. C., & Braunwald, E. (2008). The first patient clinically diagnosed with hypertrophic cardiomyopathy. *The American journal of cardiology*, 102(10), 1418–1420. <https://doi.org/10.1016/j.amjcard.2008.08.024>
23. Brimacombe, M., Walter, D., & **Salberg, L.** (2008). Gender disparity in a large nonreferral-based cohort of hypertrophic cardiomyopathy patients. *Journal of women's health (2002)*, 17(10), 1629–1634. <https://doi.org/10.1089/jwh.2007.0734>
24. Maron, B.J. and **Salberg, L.** (2006). *Hypertrophic Cardiomyopathy: For patients, their families and interested physicians* (2nd ed.). Wiley-Blackwell.
25. **Salberg, L.** (2005). Treating hypertrophic cardiomyopathy: two views. *Journal of the American College of Cardiology*, 46(11), 2146–2147.  
<https://doi.org/10.1016/j.jacc.2005.09.011>

26. Maron, B.J. and **Salberg, L.** (2001). *Hypertrophic Cardiomyopathy: For patients, their families, and interested physicians* (1st ed). Blackwell Futura.